UCLA scientists have for the first time identified a new sodium-dependent mechanism to deliver glucose — the body’s main fuel that drives tumor growth — to pancreatic and prostate cancer cells, offering new hope in the fight against two of the deadliest forms of the disease.
These findings help to clarify that current sodium-based inhibitors and other PET imaging techniques can be used in the treatment of these abdominal cancers. The team specifically sought to identify the presence of two types of sodium glucose transporters, which help to feed cancer and are prominent in these areas of the body. Though they have been extensively researched in association with other diseases, their relationship with cancer was not yet evaluated.
The study’s lead author, Ernest Wright, a professor of physiology, said “This is exciting because it provides strong evidence that SGLT2 inhibitors, such as those currently approved by the FDA to treat diseases like diabetes, could potentially block glucose uptake and reduce tumor growth and survival in pancreatic and prostate cancers.”
As two of the most deadly cancers, new methods of treatment are urgently needed. Though more research is needed to prove the effectiveness of SGLT2 inhibitors in humans, this discovery is no doubt ground-breaking in the world of cancer research.
Cancer Cures Investigated is very excited about this new development. When asked about the news, Nora Markin, a representative for the company, said “This just reiterates what many have been saying for years – the research we have, and what we know about cancer, could just be the tip of the iceberg. The human body is such a mystery, and only now are we finally beginning to de-code it. But this discovery is a step in the right direction, and will hopefully be followed by many more amazing breakthroughs.”
Those interested in learning more should visit http://www.cancercuresinvestigated.com/uncategorized/scientists-fuel-method. While there, readers are invited to take full advantage of the wealth of information available on the company site.
Release ID: 87254